Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioRestorative Therapies, Inc.

1.78
+0.02001.14%
Volume:1.72K
Turnover:3.08K
Market Cap:13.36M
PE:-1.54
High:1.79
Open:1.79
Low:1.78
Close:1.76
Loading ...

BRTX-100 Front and Center at ORS 2025

GlobeNewswire
·
10 Feb

BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Shift From Loss To Profit

Simply Wall St.
·
05 Feb

BRIEF-Biorestorative Therapies Inc - Patent Protection Expected Until April 2040

Reuters
·
05 Dec 2024

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting Thermostem® Metabolic Disease Program

THOMSON REUTERS
·
05 Dec 2024

BioRestorative Therapies Inc - Patent Protection Expected Until April 29, 2040

THOMSON REUTERS
·
05 Dec 2024

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

GlobeNewswire
·
05 Dec 2024

BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
15 Nov 2024

BioRestorative Therapies Shares up 1.8% After Prelim Mid-Stage Data for Lead Cell Therapy Candidate

THOMSON REUTERS
·
13 Nov 2024

BioRestorative Therapies Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

BRIEF-Biorestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

Reuters
·
13 Nov 2024

BUZZ-BioRestorative rises on preliminary data for bone disease cell therapy

Reuters
·
13 Nov 2024

BioRestorative Therapies Shares up 6.7% Premarket After Prelim Mid-Stage Data for Lead Cell Therapy Candidate

THOMSON REUTERS
·
13 Nov 2024

BioRestorative Therapies Inc - Blinded Preliminary Data Demonstrate a Positive Trend and Clear Signal in Primary and Secondary Endpoints

THOMSON REUTERS
·
13 Nov 2024

BioRestorative Therapies Inc - Patient Reported Efficacy Outcomes Show a Material Decrease in Pain and Increase in Function

THOMSON REUTERS
·
13 Nov 2024

BioRestorative Therapies Reports Positive Preliminary Phase 2 Brtx-100 Clinical Data

THOMSON REUTERS
·
13 Nov 2024

BioRestorative Therapies Inc - Confident That Phase 2 Trial Will Meet Its Primary and Secondary End Points

THOMSON REUTERS
·
13 Nov 2024

BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

GlobeNewswire
·
13 Nov 2024

BioRestorative Therapies Q3 EPS $(0.13) Beats $(0.43) Estimate, Sales $233.60K Miss $350.00K Estimate

Benzinga
·
13 Nov 2024

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire
·
13 Nov 2024

BioRestorative Therapies Inc expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
09 Nov 2024